"Lopinavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A.
| Descriptor ID |
D061466
|
| MeSH Number(s) |
D03.383.742.698.553
|
| Concept/Terms |
Lopinavir- Lopinavir
- N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
|
Below are MeSH descriptors whose meaning is more general than "Lopinavir".
Below are MeSH descriptors whose meaning is more specific than "Lopinavir".
This graph shows the total number of publications written about "Lopinavir" by people in this website by year, and whether "Lopinavir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lopinavir" by people in Profiles.
-
COVID-19 vaccination modified the effect of nirmatrelvir-ritonavir on post-acute mortality and rehospitalization: a retrospective cohort study. Emerg Microbes Infect. 2024 Dec; 13(1):2421397.
-
Factors associated with the acceptability of Lopinavir/Ritonavir formulations among children living with HIV/AIDS attending care and treatment clinics in Mbeya and Mwanza, Tanzania. PLoS One. 2024; 19(1):e0292424.
-
Vitamin D Assessment Over 48 Weeks in Treatment-Naive HIV Individuals Starting Lopinavir/Ritonavir Monotherapy. Curr HIV Res. 2021; 19(1):61-72.
-
Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies. Hum Reprod. 2020 08 01; 35(8):1781-1796.
-
Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. Gut. 2021 Apr; 70(4):733-742.
-
Cryptococcal meningitis and immune reconstitution inflammatory syndrome in a pediatric patient with HIV after switching to second line antiretroviral therapy: a case report. BMC Infect Dis. 2020 Jan 21; 20(1):68.
-
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014 Jul; 14(7):572-80.
-
Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies. AIDS. 2014 Mar 13; 28(5):791-3.
-
CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir. Drug Metab Dispos. 2012 Jan; 40(1):18-24.
-
Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults. J Int Assoc Physicians AIDS Care (Chic). 2010 Sep-Oct; 9(5):273-7.